Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H26ClN3O3.C4H6O4 |
Molecular Weight | 485.958 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCC(O)=O.COCCCN1CCC(CC1)NC(=O)C2=C3OCCC3=C(N)C(Cl)=C2
InChI
InChIKey=QZRSNVSQLGRAID-UHFFFAOYSA-N
InChI=1S/C18H26ClN3O3.C4H6O4/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14;5-3(6)1-2-4(7)8/h11-12H,2-10,20H2,1H3,(H,21,23);1-2H2,(H,5,6)(H,7,8)
Prucalopride is a novel enterokinetic compound and is the first representative of the benzofuran class. Prucalopride is a potent, selective and specific serotonin 5-HT4 receptor (5-HT4-R) agonist. Prucalopride (Resolor®), a highly selective serotonin 5-HT4 receptor agonist, is indicated in the European Economic Area for the treatment of adults with chronic idiopathic constipation (CIC) in whom laxatives have failed to provide adequate relief.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1875 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11438309 |
8.6 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | RESOLOR Approved UseResolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief Launch Date2008 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7 ng/mL |
2 mg 1 times / day steady-state, oral dose: 2 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
PRUCALOPRIDE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
109 ng × h/mL |
2 mg 1 times / day steady-state, oral dose: 2 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
PRUCALOPRIDE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1 day |
2 mg 1 times / day steady-state, oral dose: 2 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
PRUCALOPRIDE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
70% |
2 mg 1 times / day steady-state, oral dose: 2 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
PRUCALOPRIDE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Disc. AE: Nausea, Headache... Other AEs: Headache, Abdominal pain... AEs leading to discontinuation/dose reduction: Nausea (2%) Other AEs:Headache (1%) Diarrhea (1%) Abdominal pain (1%) Headache (19%) Sources: Abdominal pain (16%) Upper abdominal pain (16%) Lower abdominal pain (16%) Abdominal tenderness (16%) Abdominal discomfort (16%) Epigastric discomfort (16%) Nausea (14%) Diarrhea (13%) Abdominal distension (5%) Dizziness (4%) Vomiting (3%) Flatulence (3%) Fatigue (2%) Nausea (2%) Headache (1%) Diarrhea (1%) Abdominal pain (1%) Headache (19%) Abdominal pain (16%) Upper abdominal pain (16%) Lower abdominal pain (16%) Abdominal tenderness (16%) Abdominal discomfort (16%) Epigastric discomfort (16%) Nausea (14%) Diarrhea (13%) Abdominal distension (5%) Dizziness (4%) Vomiting (3%) Flatulence (3%) Fatigue (2%) |
10 mg 1 times / day multiple, oral Highest studied dose Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
healthy n = 60 Health Status: healthy Population Size: 60 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal pain | 1% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Diarrhea | 1% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Headache | 1% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Abdominal pain | 1% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Diarrhea | 1% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Headache | 1% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Diarrhea | 13% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Diarrhea | 13% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Nausea | 14% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Nausea | 14% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Abdominal discomfort | 16% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Abdominal discomfort | 16% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Abdominal pain | 16% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Abdominal pain | 16% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Abdominal tenderness | 16% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Abdominal tenderness | 16% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Epigastric discomfort | 16% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Epigastric discomfort | 16% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Lower abdominal pain | 16% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Lower abdominal pain | 16% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Upper abdominal pain | 16% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Upper abdominal pain | 16% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Headache | 19% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Headache | 19% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Fatigue | 2% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Fatigue | 2% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Nausea | 2% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Nausea | 2% Disc. AE |
2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Flatulence | 3% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Flatulence | 3% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Vomiting | 3% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Vomiting | 3% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Dizziness | 4% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Dizziness | 4% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Abdominal distension | 5% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Abdominal distension | 5% | 2 mg 1 times / day steady, oral Recommended Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: |
unhealthy, 47 years (range: 17-95 years) n = 1251 Health Status: unhealthy Condition: chronic idiopathic constipation Age Group: 47 years (range: 17-95 years) Sex: M+F Population Size: 1251 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 >100 uM] | ||||
no [IC50 >100 uM] | ||||
no [IC50 >100 uM] | ||||
no [IC50 >100 uM] | ||||
no [IC50 >100 uM] | ||||
no [IC50 >100 uM] | ||||
no [IC50 >100 uM] | ||||
no [IC50 >100 uM] | ||||
no [IC50 >=300 uM] | ||||
no [IC50 >=300 uM] | ||||
no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210166Orig1s000MultidisciplineR.pdf#page=189 Page: 189.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210166Orig1s000MultidisciplineR.pdf#page=189 Page: 189.0 |
no | |||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210166Orig1s000MultidisciplineR.pdf#page=189 Page: 189.0 |
weak | |||
yes [IC50 38 uM] | weak (co-administration study) Comment: administered with dextromethorphan; in vivo DDI potential via inhibition of CYP2D6 appears low at the proposed dose Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210166Orig1s000MultidisciplineR.pdf#page=188 Page: 188.0 |
|||
yes [IC50 4 uM] | ||||
yes [IC50 69 uM] | ||||
yes [IC50 7.8 uM] | ||||
yes [IC50 9.4 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210166Orig1s000MultidisciplineR.pdf#page=187 Page: 188;189 |
yes [Km 116 uM] | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210166Orig1s000MultidisciplineR.pdf#page=187 Page: 188;189 |
yes [Km 15 uM] | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210166Orig1s000MultidisciplineR.pdf#page=100 Page: 100;187 |
yes | weak (co-administration study) Comment: co-administration of ketoconazole increased the Cmax and AUCtau of prucalopride at steady state by 38% and 37%, respectively; Administration of erythromycin, probenecid, cimetidine, and paroxetine did not have a significant effect on the PK of prucalopride (<10% change in Cmax and AUC) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210166Orig1s000MultidisciplineR.pdf#page=100 Page: 100;187 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Structure of the human serotonin 5-HT4 receptor gene and cloning of a novel 5-HT4 splice variant. | 2000 Feb |
|
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. | 2001 |
|
Serotoninergic neuroenteric modulators. | 2001 Dec 15 |
|
The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. | 2001 Jun 29 |
|
Characterization of the receptors involved in the 5-HT-induced excitation of canine antral longitudinal muscle. | 2001 Nov |
|
The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. | 2001 Nov 30 |
|
Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. | 2001 Oct |
|
Central serotonin4 receptors selectively regulate the impulse-dependent exocytosis of dopamine in the rat striatum: in vivo studies with morphine, amphetamine and cocaine. | 2002 Dec |
|
Emerging treatments for irritable bowel syndrome. | 2002 Jan |
|
Irritable bowel syndrome: update on pathogenesis and management. | 2002 Jan-Mar |
|
Prucalopride, a systemic enterokinetic, for the treatment of constipation. | 2002 Jul |
|
New and emerging treatments for irritable bowel syndrome and functional dyspepsia. | 2002 May |
|
Gateways to clinical trials. | 2002 Oct |
|
5-HT4 receptors exert a frequency-related facilitatory control on dorsal raphé nucleus 5-HT neuronal activity. | 2002 Sep |
|
Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. | 2003 |
|
[Visceral hypersensitivity: a concept within our reach]. | 2003 Jan |
|
The serotonin 5-HT4 receptor and the amyloid precursor protein processing. | 2003 Jan-Feb |
|
Irritable bowel syndrome: an overview of diagnosis and pharmacologic treatment. | 2003 Jun |
|
Gateways to clinical trials. | 2003 May |
|
Gateways to clinical trials. | 2003 Oct |
|
Gastrointestinal motility disorders and gastrointestinal prokinetic therapy. | 2003 Sep |
|
Effect of enterokinetic prucalopride on intestinal motility in fast rats. | 2003 Sep |
|
Modulation of hippocampal excitability by 5-HT4 receptor agonists persists in a transgenic model of Alzheimer's disease. | 2004 |
|
New and emerging treatment options for chronic constipation. | 2004 |
|
Presynaptic modulation of cholinergic and non-cholinergic fast synaptic transmission in the myenteric plexus of guinea pig ileum. | 2004 Jun |
|
Frontocortical 5-HT4 receptors exert positive feedback on serotonergic activity: viral transfections, subacute and chronic treatments with 5-HT4 agonists. | 2005 Apr 15 |
|
5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j mice. | 2007 Apr |
|
Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. | 2007 Aug |
|
The serotonin signaling system: from basic understanding to drug development for functional GI disorders. | 2007 Jan |
|
Little or no ability of obestatin to interact with ghrelin or modify motility in the rat gastrointestinal tract. | 2007 Jan |
|
The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. | 2007 Jan 12 |
|
Gateways to clinical trials. July-August 2008. | 2008 Jul-Aug |
|
Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl/6j mice. | 2008 Mar 5 |
|
Gateways to clinical trials. | 2008 Oct |
|
Gateways to clinical trials. | 2008 Sep |
|
Prucalopride. | 2009 |
|
Translating 5-HT receptor pharmacology. | 2009 Dec |
|
Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. | 2009 Mar |
|
Effect of ICU interventions on gastrointestinal motility. | 2010 Apr |
|
Prucalopride for constipation. | 2010 Feb |
|
Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation. | 2010 Feb |
|
[New drugs for the treatment of constipation]. | 2010 Jul |
Patents
Sample Use Guides
Adults: 2 mg once daily with or without food, at any time of the day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26427584
Cell shortening and real-time Ca(2+) measurements were processed on field-stimulated intact cardiomyocytes with the selective 5-HT4R agonist, prucalopride (1 uM).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47794
Created by
admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
RESOLOR (AUTHORIZED: CONSTIPATION)
Created by
admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
YY-101
Created by
admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
|
PRIMARY | |||
|
DTXSID701027749
Created by
admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
|
PRIMARY | |||
|
4V2G75E1CK
Created by
admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
|
PRIMARY | |||
|
9870009
Created by
admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
|
PRIMARY | |||
|
SUB28850
Created by
admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
|
PRIMARY | |||
|
2107309
Created by
admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
|
PRIMARY | |||
|
C152112
Created by
admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
|
PRIMARY | |||
|
179474-85-2
Created by
admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
|
PRIMARY | |||
|
100000092989
Created by
admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
|
PRIMARY | |||
|
CHEMBL117287
Created by
admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
|
PRIMARY | |||
|
DBSALT002626
Created by
admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
|
PRIMARY | |||
|
4V2G75E1CK
Created by
admin on Fri Dec 15 15:32:35 GMT 2023 , Edited by admin on Fri Dec 15 15:32:35 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD